Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
Palm oil Market PPT: Opportunities by Types, Demand, Top Manufactures and Ap...IMARC Group
According to the latest report by IMARC Group, the global palm oil market size reached US$ 48.10 Billion in 2020.
Palm oil is a reddish, edible vegetable oil produced from the mesocarp of oil palm fruits. As compared to other oils, it is a rich source of antioxidants, vitamin E, and carotene.
Other than this, palm oil remains stable at high temperatures, which makes it ideal for deep frying applications.
Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects.
https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline-Review,-H1-2013/
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing. It is working towards FDA approval for human cancer indications like skin cancer. RadioGel consists of radioactive yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. It is led by an experienced management team and advises by world-class medical and scientific boards.
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
Palm oil Market PPT: Opportunities by Types, Demand, Top Manufactures and Ap...IMARC Group
According to the latest report by IMARC Group, the global palm oil market size reached US$ 48.10 Billion in 2020.
Palm oil is a reddish, edible vegetable oil produced from the mesocarp of oil palm fruits. As compared to other oils, it is a rich source of antioxidants, vitamin E, and carotene.
Other than this, palm oil remains stable at high temperatures, which makes it ideal for deep frying applications.
Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects.
https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline-Review,-H1-2013/
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing. It is working towards FDA approval for human cancer indications like skin cancer. RadioGel consists of radioactive yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. It is led by an experienced management team and advises by world-class medical and scientific boards.
The report provides a complete roadmap for setting up a Rabeprazole (Aciphex) manufacturing plant. It covers a comprehensive market overview to micro-level information such as unit operations involved, raw material requirements, utility requirements, infrastructure requirements, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, etc.
QIAGEN exceeded its goal of placing over 750 of its QIAsymphony modular laboratory automation systems in 2012, up from over 550 in 2011. The company expects placements to exceed 1,000 by the end of 2013. Approximately 70% of placements so far have been with molecular diagnostics customers. QIAsymphony offers integrated sample processing and real-time PCR and gives customers access to commercial assays while allowing custom tests.
The future of the cannabis industry is in technology, World-Class Extractions is positioned to be a leader with its state-of-the-art extraction and processing technology! Learn more about cannabis technology and World-Class Extractions (CSE:$PUMP) unique and innovation driven business model.
This investor presentation provides an overview of Viropro, Inc., a contract development and manufacturing organization for biotech drugs. It discusses the growing market opportunity in outsourcing biopharmaceutical R&D and manufacturing services. Viropro plans to build a global network through acquisitions like Alpha Biologics, which owns an FDA-compliant biomanufacturing facility in Malaysia. This "string of pearls" model across Asia and Europe is aimed to provide world-class development and manufacturing services to biotech companies in a cost-effective manner. The presentation makes the case that an investment of $40 million in Viropro over two funding rounds could yield a return of 10x and 46% IRR through an
Piramal Clinical Trial Services provides clinical trial manufacturing capabilities including packaging, storage, distribution, and reconciliation of investigational drugs. They offer primary and secondary packaging, kit preparation and compilation, temperature controlled storage and distribution, returns management, and support services globally. Piramal aims to offer superior customer service and uses a digital platform called TrakPack to track manufacturing, distribution, returns, and provide reporting to customers.
The document discusses key aspects of current good manufacturing practices (cGMP) for pharmaceuticals. It defines cGMP and explains that the "C" stands for "current," meaning manufacturers must use up-to-date technologies and systems. cGMP covers all aspects of production from facilities, equipment, personnel, packaging, quality control, and documentation. Following cGMP is important because it helps ensure the quality, safety and effectiveness of drugs. Historical incidents like the thalidomide tragedy and Tylenol tampering case demonstrate how non-compliance with GMP can put patients' lives at risk.
Advanced Medical Isotope Corporation is developing a brachytherapy device called RadioGel for cancer treatment in humans and animals. It plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. It has the potential to treat multiple cancer types more effectively than existing therapies.
Advanced Medical Isotope Corporation is developing a brachytherapy device called RadioGel for cancer treatment in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for human use. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel that solidifies inside the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing deals. It is working with national labs and universities to optimize the device and treatment techniques.
Pas Reform Times 2014 - Home of Hatchery InnovationHenry Arts
Read about the latest developments in Hatchery Innovation from Pas Reform Times. In this issue: Projects around the world, Expansion to the US with NatureForm Hatchery Technologies and Hatchery Automation.
GMP (good manufacturing practices) and cGMP (current good manufacturing practices) are quality standards for the manufacture of pharmaceutical products and medical devices. They help ensure that products are consistently produced and controlled according to quality standards for safety and efficacy. Key aspects of GMP include establishing processes and procedures for production, cleaning, maintenance, personnel training, and quality testing of products. Following GMP guidelines helps manufacturers produce pharmaceuticals that meet the necessary quality standards.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient production capacity through 2015.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date. Visit CANFinfo.com to learn more.
This document provides an agenda and presentation for a meeting with investors about Braskem. The summary is:
1) Braskem is a leading petrochemical company in the Americas and largest biopolymer producer worldwide, with operations in Brazil, USA, Germany and Mexico.
2) The presentation discusses Braskem's business model, strategy drivers, risks and opportunities, sustainable development efforts, and 2015 financial results.
3) It also provides an overview of Braskem's ownership structure, governance, raw material sourcing and diversification efforts, and competitive position relative to its peers.
This report provides an analysis of the product pipeline of Eqalix, Inc., a biotechnology company developing novel nano-materials for tissue repair and regeneration. The report details Eqalix's six pipeline products which are in various stages of development, including plant-protein based nano-fiber scaffolds and small-diameter hybrid blood vessels. Each product's description, development status and indication are described. The report also provides an overview of Eqalix's business and locations, and is intended to help readers understand Eqalix's portfolio and commercialization strategy.
(1) Nemaura Medical is developing a non-invasive, flexible continuous glucose monitor called SugarBEAT that consists of a daily disposable skin patch, transmitter, and app. It aims to expand CGM use beyond insulin users to all diabetics and pre-diabetics, a total addressable market of $82 billion.
(2) Interim data from Nemaura's FDA clinical trial showed SugarBEAT achieved a mean absolute relative difference (MARD) of 8.77% for 1-point calibration and 7.97% for 2-point calibration, outperforming Dexcom G5. Commercial launch in the UK is expected in Q4 2018 with FDA approval and US launch anticipated
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date. Visit CANFinfo.com to learn
The report provides a complete roadmap for setting up a Rabeprazole (Aciphex) manufacturing plant. It covers a comprehensive market overview to micro-level information such as unit operations involved, raw material requirements, utility requirements, infrastructure requirements, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, etc.
QIAGEN exceeded its goal of placing over 750 of its QIAsymphony modular laboratory automation systems in 2012, up from over 550 in 2011. The company expects placements to exceed 1,000 by the end of 2013. Approximately 70% of placements so far have been with molecular diagnostics customers. QIAsymphony offers integrated sample processing and real-time PCR and gives customers access to commercial assays while allowing custom tests.
The future of the cannabis industry is in technology, World-Class Extractions is positioned to be a leader with its state-of-the-art extraction and processing technology! Learn more about cannabis technology and World-Class Extractions (CSE:$PUMP) unique and innovation driven business model.
This investor presentation provides an overview of Viropro, Inc., a contract development and manufacturing organization for biotech drugs. It discusses the growing market opportunity in outsourcing biopharmaceutical R&D and manufacturing services. Viropro plans to build a global network through acquisitions like Alpha Biologics, which owns an FDA-compliant biomanufacturing facility in Malaysia. This "string of pearls" model across Asia and Europe is aimed to provide world-class development and manufacturing services to biotech companies in a cost-effective manner. The presentation makes the case that an investment of $40 million in Viropro over two funding rounds could yield a return of 10x and 46% IRR through an
Piramal Clinical Trial Services provides clinical trial manufacturing capabilities including packaging, storage, distribution, and reconciliation of investigational drugs. They offer primary and secondary packaging, kit preparation and compilation, temperature controlled storage and distribution, returns management, and support services globally. Piramal aims to offer superior customer service and uses a digital platform called TrakPack to track manufacturing, distribution, returns, and provide reporting to customers.
The document discusses key aspects of current good manufacturing practices (cGMP) for pharmaceuticals. It defines cGMP and explains that the "C" stands for "current," meaning manufacturers must use up-to-date technologies and systems. cGMP covers all aspects of production from facilities, equipment, personnel, packaging, quality control, and documentation. Following cGMP is important because it helps ensure the quality, safety and effectiveness of drugs. Historical incidents like the thalidomide tragedy and Tylenol tampering case demonstrate how non-compliance with GMP can put patients' lives at risk.
Advanced Medical Isotope Corporation is developing a brachytherapy device called RadioGel for cancer treatment in humans and animals. It plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. It has the potential to treat multiple cancer types more effectively than existing therapies.
Advanced Medical Isotope Corporation is developing a brachytherapy device called RadioGel for cancer treatment in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for human use. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel that solidifies inside the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing deals. It is working with national labs and universities to optimize the device and treatment techniques.
Pas Reform Times 2014 - Home of Hatchery InnovationHenry Arts
Read about the latest developments in Hatchery Innovation from Pas Reform Times. In this issue: Projects around the world, Expansion to the US with NatureForm Hatchery Technologies and Hatchery Automation.
GMP (good manufacturing practices) and cGMP (current good manufacturing practices) are quality standards for the manufacture of pharmaceutical products and medical devices. They help ensure that products are consistently produced and controlled according to quality standards for safety and efficacy. Key aspects of GMP include establishing processes and procedures for production, cleaning, maintenance, personnel training, and quality testing of products. Following GMP guidelines helps manufacturers produce pharmaceuticals that meet the necessary quality standards.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient production capacity through 2015.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date. Visit CANFinfo.com to learn more.
This document provides an agenda and presentation for a meeting with investors about Braskem. The summary is:
1) Braskem is a leading petrochemical company in the Americas and largest biopolymer producer worldwide, with operations in Brazil, USA, Germany and Mexico.
2) The presentation discusses Braskem's business model, strategy drivers, risks and opportunities, sustainable development efforts, and 2015 financial results.
3) It also provides an overview of Braskem's ownership structure, governance, raw material sourcing and diversification efforts, and competitive position relative to its peers.
This report provides an analysis of the product pipeline of Eqalix, Inc., a biotechnology company developing novel nano-materials for tissue repair and regeneration. The report details Eqalix's six pipeline products which are in various stages of development, including plant-protein based nano-fiber scaffolds and small-diameter hybrid blood vessels. Each product's description, development status and indication are described. The report also provides an overview of Eqalix's business and locations, and is intended to help readers understand Eqalix's portfolio and commercialization strategy.
(1) Nemaura Medical is developing a non-invasive, flexible continuous glucose monitor called SugarBEAT that consists of a daily disposable skin patch, transmitter, and app. It aims to expand CGM use beyond insulin users to all diabetics and pre-diabetics, a total addressable market of $82 billion.
(2) Interim data from Nemaura's FDA clinical trial showed SugarBEAT achieved a mean absolute relative difference (MARD) of 8.77% for 1-point calibration and 7.97% for 2-point calibration, outperforming Dexcom G5. Commercial launch in the UK is expected in Q4 2018 with FDA approval and US launch anticipated
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date. Visit CANFinfo.com to learn
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
KEY Points of Leicester travel clinic In London doc.docxNX Healthcare
In order to protect visitors' safety and wellbeing, Travel Clinic Leicester offers a wide range of travel-related health treatments, including individualized counseling and vaccines. Our team of medical experts specializes in getting people ready for international travel, with a particular emphasis on vaccines and health consultations to prevent travel-related illnesses. We provide a range of travel-related services, such as health concerns unique to a trip, prevention of malaria, and travel-related medical supplies. Our clinic is dedicated to providing top-notch care, keeping abreast of the most recent recommendations for vaccinations and travel health precautions. The goal of Travel Clinic Leicester is to keep you safe and well-rested no matter what kind of travel you choose—business, pleasure, or adventure.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
MBC Support Group for Black Women – Insights in Genetic Testing.pdfbkling
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Under Pressure : Kenneth Kruk's StrategyKenneth Kruk
Kenneth Kruk's story of transforming challenges into opportunities by leading successful medical record transitions and bridging scientific knowledge gaps during COVID-19.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
1. Page 1 of 3
Acasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with New
Continuous Manufacturing Process
Laval, Québec, CANADA – May 31, 2017 – Acasti Pharma Inc. (NASDAQ:ACST – TSX-V:ACST) today announced
the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s
omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous
manufacturing process developed in partnership with CordenPharma. CaPre is a potentially best-in-class
omega-3 drug derived of krill oil and being developed for the treatment of patients with hypertriglyceridemia,
a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis. The process was
jointly designed and implemented by the Acasti and CordenPharma technical teams and engineers at the
CordenPharma Chenôve facility in Dijon, France.
“The development and implementation of this continuous manufacturing production line is evidence of the
terrific progress Acasti is making as we prepare to initiate Phase 3 trials of CaPre in late 2017,” said Pierre
Lemieux, Ph.D., chief operating officer of Acasti Pharma. “It was a successful joint effort involving Acasti and
CordenPharma to design and execute a process that paves the way for the development and future
commercial manufacturing of CaPre as a potential treatment for patients with severe hypertriglyceridemia.
This is an important milestone in Acasti Pharma’s program to develop and commercialize CaPre.”
This continuous manufacturing process allows for the production of CaPre with an increased throughput and a
small equipment footprint. The process is designed to purify the bioactive molecules of the raw krill oil through
continuous and consecutive decantations. This approach will enable improved quality control and cGMP
compliance, while reducing energy consumption, waste and raw material, in a cost-effective manner that
aligns with the FDA’s championing of robust, flexible and efficient continuous manufacturing processes.
“We worked closely with Acasti Pharma to design and engineer a unique and innovative continuous
manufacturing process for CaPre,” said Yves Michon, chief executive officer of CordenPharma Chenôve. “This
process has been installed at CordenPharma Chenôve and will allow us to efficiently scale-up the volume of
CaPre needed for Acasti‘s Phase 3 trial and early commercial demand. We are honored to continue working
with them.”
About Acasti Pharma
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular
drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting
an estimated one third of the U.S. population. The corporation’s strategy is to initially develop and
commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its
founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and
well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with
cardiovascular disease risk. For more information, visit www.acastipharma.com.
About CordenPharma
CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical
Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs,
Drug Products, and associated Packaging Services. Through a network of fully-inspected cGMP facilities across
2. Page 2 of 3
Europe and the US organized under five Technology Platforms – Peptides, Oligonucleotides, Lipids &
Carbohydrates; Injectables; Highly Potent & Oncology; Small Molecules; and Antibiotics, CordenPharma
experts translate complex processes, ideas and projects at any stage of development into high-value products.
For more information visit www.cordenpharma.com. Inquiries: www.cordenpharma.com/contact-us/
CordenPharma Chenôve is a cGMP manufacturer of APIs and advanced pharmaceutical intermediates,
specializing in the design of synthetic routes and development processes for new products from laboratory to
commercial scale, with equipment and chemical technologies that are particularly suitable for multi-step
synthesis. www.cordenpharma.com/facilities/chenove/
Forward Looking Statements
Statements in this press release that are not statements of historical or current fact constitute “forward
looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-
looking statements involve known and unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Acasti to be materially different from historical results or from any future results
expressed or implied by such forward-looking statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are
cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of
this press release.
The forward-looking statements contained in this news release are expressly qualified in their entirety by this
cautionary statement and the “Cautionary Note Regarding Forward-Looking Information” section contained in
Acasti’s latest Annual Information Form, which also forms part of Acasti’s latest annual report on Form 20-F,
and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the
investor section of Acasti’s website at acastipharma.com (the “AIF”). All forward-looking statements in this
press release are made as of the date of this press release. Acasti does not undertake to update any such
forward-looking statements whether as a result of new information, future events or otherwise, except as
required by law. The forward-looking statements contained herein are also subject generally to other risks and
uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and
Exchange Commission and the Canadian securities commissions. Additional information about these
assumptions and risks and uncertainties is contained in the AIF under “Risk Factors.”
Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
SOURCE: Acasti Pharma Inc.
Acasti Contact:
Jan D’Alvise
Chief Executive Officer
450-686-4555
info@acastipharma.com
www.acastipharma.com
CordenPharma Contact:
Abby Thompson
Global Marketing Communications Manager
3. 3 of 3
T +1 617 909 5312
abby.thompson@cordenpharma.com
www.cordenpharma.com
Acasti Media & Investor Contact:
Jessica Dyas
Canale Communications
619-849-5385
jessica@canalecomm.com